Update
$Jaguar Health(JAGX.US$ Jaguar Health Regains Compliance With Nasdaq's Bid Price Requirement
Accesswire· 1 min ago
JAGX's securities continue to be listed and traded on Nasdaq
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024
Accesswire· 1 min ago
JAGX's securities continue to be listed and traded on Nasdaq
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
